Short Interest in Blueprint Medicines Co. (NASDAQ:BPMC) Grows By 16.9%
Short Interest in Blueprint Medicines Co. (NASDAQ:BPMC) Grows By 16.9%
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 5,520,000 shares, a growth of 16.9% from the August 15th total of 4,720,000 shares. Based on an average daily volume of 980,900 shares, the short-interest ratio is presently 5.6 days. Currently, 9.6% of the shares of the company are short sold.
蓝图医药股份有限公司(纳斯达克代码:BPMC-GET评级)在8月份看到空头股数业务大幅增长。截至8月31日,空头股数共有552万股,比8月15日472万股的总数增长了16.9%。以日均成交量98.09万股计算,目前短息比率为5.6天。目前,该公司9.6%的股份被卖空。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
BPMC has been the topic of a number of research reports. Morgan Stanley raised their price target on shares of Blueprint Medicines from $65.00 to $80.00 and gave the company an "equal weight" rating in a research note on Friday, September 9th. Raymond James decreased their price target on shares of Blueprint Medicines from $133.00 to $115.00 and set a "strong-buy" rating on the stock in a research note on Wednesday, August 3rd. Stifel Nicolaus raised their price target on shares of Blueprint Medicines from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Thursday, August 18th. The Goldman Sachs Group raised their price target on shares of Blueprint Medicines from $126.00 to $143.00 and gave the company a "buy" rating in a research note on Wednesday, August 3rd. Finally, HC Wainwright decreased their price target on shares of Blueprint Medicines from $100.00 to $80.00 and set a "buy" rating on the stock in a research note on Wednesday, August 17th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Blueprint Medicines has a consensus rating of "Moderate Buy" and a consensus price target of $92.06.
BPMC已经成为许多研究报告的主题。9月9日,周五,摩根士丹利在一份研究报告中将蓝图医药的目标价从65.00美元上调至80.00美元,并给予该公司“同等权重”的评级。8月3日,雷蒙德·詹姆斯在一份研究报告中将Blueprint Medicines的目标股价从133.00美元下调至115.00美元,并将该股的评级定为“强势买入”。8月18日,Stifel Nicolaus在一份研究报告中将Blueprint Medicines的目标价从93美元上调至100.00美元,并给予该公司“买入”评级。高盛夫妇将蓝图医药的目标股价从126.00美元上调至143.00美元,并在8月3日周三的一份研究报告中给出了该公司“买入”的评级。最后,HC Wainwright将Blueprint Medicines的股票目标价从100.00美元下调至80美元,并在8月17日星期三的一份研究报告中对该股设定了“买入”评级。两名研究分析师对该股的评级为卖出,四名分析师给予该股持有评级,八名分析师给予该股买入评级,一名分析师给予该股强烈买入评级。根据MarketBeat的数据,Blueprint Medicines的共识评级为“适度买入”,共识目标价为92.06美元。
Insiders Place Their Bets
内部人士下注
In other news, SVP Christopher K. Murray sold 2,500 shares of the firm's stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $60.44, for a total transaction of $151,100.00. Following the sale, the senior vice president now directly owns 21,320 shares in the company, valued at approximately $1,288,580.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Jeffrey W. Albers sold 20,000 shares of the firm's stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $68.41, for a total transaction of $1,368,200.00. Following the sale, the director now directly owns 183,243 shares in the company, valued at approximately $12,535,653.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Christopher K. Murray sold 2,500 shares of the firm's stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $60.44, for a total value of $151,100.00. Following the sale, the senior vice president now owns 21,320 shares in the company, valued at $1,288,580.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 47,500 shares of company stock valued at $3,300,123. Company insiders own 3.42% of the company's stock.
在其他新闻方面,高级副总裁克里斯托弗·K·默里在一笔日期为8月4日星期四的交易中出售了2500股该公司股票。该股以60.44美元的平均价格出售,总成交金额为151,100.00美元。出售后,高级副总裁现在直接拥有该公司21,320股,价值约1,288,580.80美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,可以通过这个超级链接获得。其他新闻方面,董事杰弗里·W·阿尔伯斯在一笔日期为8月16日(星期二)的交易中出售了20,000股该公司股票。该股以68.41美元的平均价格出售,总成交金额为1,368,200.00美元。交易完成后,董事现在直接拥有该公司183,243股,价值约12,535,653.63美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,可以通过这个超级链接获得。此外,高级副总裁克里斯托弗·K·默里在一笔日期为8月4日(星期四)的交易中出售了2500股公司股票。这些股票的平均价格为60.44美元,总价值为151,100.00美元。出售后,高级副总裁现在拥有该公司21,320股,价值1,288,580.80美元。此次拍卖的披露信息可在此处找到。在过去的三个月里,内部人士已经出售了47,500股公司股票,价值3,300,123美元。公司内部人士持有该公司3.42%的股份。
Hedge Funds Weigh In On Blueprint Medicines
对冲基金看好Blueprint Medicines
Blueprint Medicines Stock Up 1.3 %
Blueprint Medicines股票上涨1.3%
Shares of NASDAQ BPMC traded up $0.92 during midday trading on Monday, reaching $70.15. 22,685 shares of the stock were exchanged, compared to its average volume of 783,081. The company has a 50 day simple moving average of $64.87 and a 200 day simple moving average of $60.99. Blueprint Medicines has a twelve month low of $43.46 and a twelve month high of $117.86.
周一午盘,纳斯达克股价上涨0.92美元,至70.15美元。该股成交22,685股,而其平均成交量为783,081股。该公司的50日简单移动均线切入位在64.87美元,200日简单移动均线切入位在60.99美元。Blueprint Medicines的12个月低点为43.46美元,12个月高位为117.86美元。
Blueprint Medicines (NASDAQ:BPMC – Get Rating) last announced its quarterly earnings results on Tuesday, August 2nd. The biotechnology company reported ($2.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.23) by ($0.45). Blueprint Medicines had a negative return on equity of 45.89% and a negative net margin of 304.41%. The firm had revenue of $36.55 million for the quarter, compared to analyst estimates of $37.61 million. During the same quarter in the prior year, the business earned ($1.86) EPS. The firm's quarterly revenue was up 33.9% on a year-over-year basis. On average, equities research analysts predict that Blueprint Medicines will post -9.35 earnings per share for the current year.
Blueprint Medicines(纳斯达克代码:BPMC-GET Rating)上一次公布季度收益是在8月2日(星期二)。这家生物技术公司公布的季度每股收益(EPS)为2.68美元,低于分析师普遍预期的2.23美元和0.45美元。Blueprint Medicines的净资产回报率为负45.89%,净利润率为负304.41%。该公司本季度营收为3,655万美元,而分析师预期为3,761万美元。在上一年的同一季度,该业务的每股收益为1.86美元。该公司季度营收同比增长33.9%。平均而言,股票研究分析师预测,Blueprint Medicines本年度每股收益将达到9.35美元。
Blueprint Medicines Company Profile
蓝图医药公司简介
(Get Rating)
(获取评级)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.
BluePrint Medicines Corporation是一家精准治疗公司,在美国和国际上开发针对基因定义的癌症和血液疾病的药物。该公司正在开发用于治疗全身性肥大细胞增多症(SM)和胃肠道间质瘤的AYVAKIT;用于治疗非进展性肥大细胞增多症和其他肥大细胞疾病的口服可用、有效的试剂盒抑制剂BLU-263;以及用于治疗肝细胞癌的口服可用且有效的抑制剂Fisogatinib。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Blueprint Medicines (BPMC)
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
- 免费获取StockNews.com关于蓝图药物的研究报告(BPMC)
- 仍然爱着它:投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗?
- 自动区重新进入拉力赛模式,新高在望
- Upwork股价跌入便宜货领域
- 克罗格百货是你的一站式消费者史泰博股票
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
接受蓝图药物日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Blueprint Medicines和相关公司的最新新闻和分析师评级的每日摘要。